- Home
- NODK vs FENC Comparison
NODK vs FENC Comparison
Compare NODK & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- FENC
- Stock Information
- Founded
- NODK 1946
- FENC 1996
- Country
- NODK United States
- FENC United States
- Employees
- NODK N/A
- FENC N/A
- Industry
- NODK Property-Casualty Insurers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- FENC Health Care
- Exchange
- NODK Nasdaq
- FENC Nasdaq
- Market Cap
- NODK 277.0M
- FENC 225.4M
- IPO Year
- NODK 2017
- FENC 2001
- Fundamental
- Price
- NODK $13.35
- FENC $8.76
- Analyst Decision
- NODK
- FENC Strong Buy
- Analyst Count
- NODK 0
- FENC 2
- Target Price
- NODK N/A
- FENC $13.50
- AVG Volume (30 Days)
- NODK 11.7K
- FENC 56.4K
- Earning Date
- NODK 11-06-2025
- FENC 11-06-2025
- Dividend Yield
- NODK N/A
- FENC N/A
- EPS Growth
- NODK N/A
- FENC N/A
- EPS
- NODK 0.07
- FENC N/A
- Revenue
- NODK $310,389,000.00
- FENC $33,302,000.00
- Revenue This Year
- NODK N/A
- FENC $0.96
- Revenue Next Year
- NODK N/A
- FENC $51.71
- P/E Ratio
- NODK $192.70
- FENC N/A
- Revenue Growth
- NODK N/A
- FENC N/A
- 52 Week Low
- NODK $12.01
- FENC $3.96
- 52 Week High
- NODK $17.24
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- NODK 55.16
- FENC 50.16
- Support Level
- NODK $12.85
- FENC $8.96
- Resistance Level
- NODK $13.60
- FENC $9.23
- Average True Range (ATR)
- NODK 0.27
- FENC 0.27
- MACD
- NODK 0.05
- FENC 0.00
- Stochastic Oscillator
- NODK 76.56
- FENC 34.57
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.